Cracking The Mental Health Crisis
And The Investment Opportunity Behind The Solution
The medical establishment has been trying to crack the depression/PTSD/anxiety code for decades, yet it remains a mystery. Not only are current treatment options inadequate, the mental health epidemic is growing worse annually while the ongoing health crisis is exacerbating the issue.
It’s a major global concern, with heavy emotional and financial costs attached.
According to the WHO depression and anxiety costs the global economy an estimated $1 trillion each year in lost productivity, with over 300 million people suffering from depression globally.
US$238 billion is spent annually on mental health treatments and ancillary services (Source: US Substance Abuse and Mental Health Administration).
Conventional Treatment For Mental Health Is Not Working
Treatment options have not changed in decades. What’s available today is hardly mitigating the devastating effects of mental illness, while leaving a trail of undesirable side effects (insomnia, loss of libido, suicidal impulses,etc).
There is a 75% non-adherence rate to anti-depressants, with relapse rates of 40% – 70% (Star*D Study).
Thankfully, science has tapped into a new source of treatment powerful enough to make incursions into the trillion dollar pharmaceutical industry.
Psychedelic Assisted Psychotherapy Gaining Momentum
“Traditional mechanisms for investing capital in psychedelics are virtually non-existent. Given the undisputed promise for psychedelic medicine, one could argue that the industry needs more investment opportunities.” – PsylocybinTechnology.com
Using psychedelic molecules to catalyze the efficacy of psychotherapy is showing great promise in the treatment of severe depression, PTSD, substance addiction and anxiety disorders.
In what could be the most important innovation in the treatment of major mental health issues, psychedelic microdosing options have come to the fore.
It’s a major breakthrough and gaining momentum, while presenting a generational, ground floor investment opportunity for early stage investors.
Results from clinical and academical studies on psychedelic-assisted psychotherapy are convincing.
What was once taboo and cliquey is going mainstream, with politicians and the medical establishment getting on board. Scientists, acclaimed doctors and world class institutions and universities are unlocking the vast potential held within active psychedelic molecules such as psilocybin and ketamine.
Advancements in cannabis related therapies are also gaining prominence, eliminating long standing barriers for healing.
While science continues to prove the efficacy of psychedelic assisted therapy, the investment opportunity is too large to overlook.
Kevin O’Leary, Bruce Linton (former CEO of US$6 billion Canopy Growth) and billionaire co-founder of PayPal Peter Thiel are already invested in the medicinal psychedelic industry.
The WHO reported in 2015 that every US$1 invested in scaling up treatment for depression and anxiety leads to a return of US$4 in better health and ability to work.(3)
“We know that treatment of depression and anxiety makes good sense for health and wellbeing; this new study confirms that it makes sound economic sense too,” said Dr Margaret Chan, Director-General of WHO.
Core One Labs Inc. (CSE: COOL, OTC: CLABD)
Penetrating A $65 Billion Industry With Effective Mental Health Treatment Offerings
“THE FEDS HAVE DESIGNATED COMPASS PATHWAYS’ EXPERIMENTAL PSILOCYBIN TREATMENT FOR DEPRESSION A ‘BREAKTHROUGH THERAPY.'” – Bloomberg Business, January 7th, 2020
5 key points outlining the Core One Labs (CSE: CORE, OTC: CLABD) opportunity:
- One of Western Canada’s largest clinics with over 250,000 patients.
- Patient database used to conduct clinical trials on psilocybin treatments.
- Patented compound delivery technology using sublingual nanostrips (CannaStrips™), expanding into psychedelic compounds.
- Over $15MM invested into state of the art CannaStrips™ production facility.
- Psychedelic realm is a generational investment opportunity providing a new platform for effective treatment of mental health disorders.
Core One Labs Inc. (CSE: COOL, OTC: CLABD) is entering a $65 billion market(1)(3) with a remarkable suite of potentially lucrative revenue streams while providing effective, safe treatment products and services to those that need it the most.
Offering one of Western Canada’s largest clinics with over 250,000 patients and plans to expand across Canada, it’s market capitalization of only $xx million provides a compelling investment opportunity against a backdrop of far more expensive peers.
The immediate market potential is huge.
- Anxiety disorder and depression treatment: $16 billion (1)
- Illustrative adult use: $10 billion (1)
- Botanical supplements: $38 billion (3)
Core One’s Market Penetration Strategy
When it comes to microdosing in psychedelic assisted psychotherapy, precision is critical. Vulnerable patients require the comfort of exacting, reliable treatment.
Core One Labs Inc. (CSE: COOL, OTC: CLABD) patented sublingual CannaStrips™ offer a revolutionary method to deliver precise, consistent dosages of the prescribed active ingredient (functional mushrooms, psilocybin, THC, CBD, etc) directly into the bloodstream without taxing the liver.
The patient is eased through a professionally guided therapy program using regulated dosages of psychedelic compounds like ketamine and psilocybin in a safe, fully supervised setting. The treatment will be used alongside psychotherapy.
These lower doses can promote better mental health by disrupting thought patterns or loops that may be preventing progress. The experience has been described as ”euphoric”, “calming” and “mystical.”
Core One Labs Inc. (CSE: COOL, OTC: CLABD) aims to introduce CannaStrips™ via its clinic located in British Columbia. One of Western Canada’s largest, with over 250,000 patients, has been operating for 8 years.
The clinic will serve as a base to provide fully integrated, seamless and safe psychedelic assisted psychotherapy, while conducting R&D and clinical trials to develop and commercialize rapid onset treatments for mental health disorders.
The company has also invested $15 million into a state-of-the-art production facility in order to control all stages of CannaStrips™ supply chain (production, distribution, transportation and delivery).
This allowsCore One Labs Inc. (CSE: COOL, OTC: CLABD) to maintain an edge in profit margin and efficiency.
The Path Forward for Psychedelic Assisted Psychotherapy
Professional psychedelic assisted therapy is a revolutionary mental health treatment concept whose time has come.
Tailwinds are strong, driving investment and research into the sector. Public awareness is growing rapidly and regulatory walls are starting to fall. This form of therapy is simply too effective to ignore.
Core One Labs Inc. (CSE: COOL, OTC: CLABD) is implementing an integrated product and service model into a sector that is ripe for rapid growth.
The process is comprehensive, yet comforting and seamless for the patient, even offering ongoing support following a treatment program.
Cross-Canada Expansion Plans Provide Exponential Growth Potential
Core One Labs Inc. (CSE: COOL, OTC:CLABD) business plan provides for multiple streams of revenue, including but not limited to:
- Psychedelic-assisted psychotherapy (PSAP) where permitted.
- Psychedelic-integrated psychotherapy (where PSAP not permitted).
- Leverage commercial relationships to expedite Phase 1 testing and novel drug development of its psychedelic formulations and proprietary delivery systems.
- Cannabis-based treatments.
By leveraging its existing SOPs, data driven research sets and practitioner education modules, Core One Labs Inc. (CSE: COOL, OTC:CLABD) aims to expand this model across Canada.
For a company that is still deemed to be a microcap stock, the potential rate of growth through expansion is enough for the most conservative speculator to take notice.
The Bottom Line
Core One Labs Inc. (CSE:CORE, OTC: CLABD) is Introducing breakthroughs in effective, safe and reliable treatments for devastating mental disorders. Guided psychedelic therapies have the potential to ease the suffering of millions. The company is addressing a $65+ billion market, with plans to introduce its patented sublingual CannaStrips™ delivery platform via professionally regulated clinics across Canada. Core One is at the ground floor of an industry being driven by research and support from renowned medical establishments and institutional investors. This backdrop provides a compelling investment opportunity for early investors as the company embarks on an aggressive growth trajectory.
- (1) Global Newswire, Reports and Data, May 2019
- (2) Source: ”Botanical Supplements Market Size and Forecast, Hexa Research
- (3) https://www.who.int/news-room/detail/13-04-2016-investing-in-treatment-for-depression-and-anxiety-leads-to-fourfold-return
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter/report/commentary piece/article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Furthermore, it is certainly possible for errors or omissions to take place regarding the profiled company, in communications, writing and/or editing.
Nothing in this publication should be considered as personalized financial advice. We are not licensed under any securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. The information provided in this article is for informational purposes only and is not a recommendation to buy or sell any security. Please consult a licensed financial advisor before making any investment decision. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. HotStocksReview.com is a website owned by Mountain Capital Corp (“Mountain”), (100 King Street West #5700, Toronto, Ontario). Mountain has been retained by Core One Labs Inc. to provide strategic digital media, marketing and data analytics services on behalf of the company for an undefined term. The agreement with Core One provides for a one-time payment of one hundred thousand U.S. dollars. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision.
By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing Mountain Capital Corp, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
Please refer to our complete Disclaimer and Disclosure here